Posted on

Publication support services by Harrisco: top academic company of Korea

 

Harrisco is a leading academic editing and translation company based in Seoul, South Korea. Ever since its inception in 1997, Harrisco has been consistently offering publication support services to researchers all across Asia. These include cover letter development, plagiarism check and rewriting, journal selection, formatting as per journal guidelines, etc.

After English editing and translation, most researchers also avail of publication support services of Harrisco. Most Asian researchers have a limited knowledge of the high standards set by international peer-reviewed journals. Therefore, they usually need publication support services. A paper may have scientifically accurate content and good English language usage, but it may still be rejected by a journal editor for not adhering to formatting guidelines of the journal.

Now, let’s understand the most popular service of publication support. It is none other than journal selection. Every academic field of study will have hundreds or thousands of academic journals for submission of manuscripts. However, Harrisco’s team of experts are PhD professionals who themselves have a track record of publication in international journals.

After carefully reviewing the content of the manuscript, they will provide names of three journals that are most suitable for publication. Journal impact factor, scope and aims of the journal, publishing model, type of manuscript, etc. are some factors considered for journal selection. Most researchers in Asia intend to publish their work in high impact factor SCI (Science Citation Index) journals. They receive research grants only after publishing in high impact journals.

The next most popular service of publication support is plagiarism check. Harrisco has a sophisticated software named CopyKiller to check the content of academic papers. Most journal editors reject a paper outright if it has plagiarized content. The content must be original and all plagiarised sentences need to rewritten in different words.

Researchers can’t just cite related works in their research paper and offer plagiarised content. The findings of related studies have to be presented in own words. Scientific editors of Harrisco provide rewriting services to researchers caught in plagiarism issues. Other important services of publication support include manuscript formatting and figure formatting.

Harrisco’s editors are well versed in several journal style guides, such as the AMA Manual of Style, The Chicago Manual of Style, or the APA Manual of Style. Most biomedical journal editors expect papers to be formatted as per the AMA Manual of Style. The title, page layout, font size, references, citations, etc. are all formatted according to a prescribed style guide or journal’s formatting guidelines displayed on the website.

Figure formatting is done by scientific illustrators who are well versed with the complex figure formatting guidelines of the journal. These rules are used for formatting figures and tables in the manuscript. Cover letter development is usually the sought after service of novice researchers who have never submitted a cover letter earlier to a journal. Manuscript preparation is a daunting task for most Asian researchers, so publication support services of Harrisco are availed by many researchers of Asia.

.

 

 

Posted on

How to do journal selection for your manuscript?

Many factors have to be considered while doing right journal selection for your manuscript. Most novice researchers do not know the factors to be considered before submitting the manuscript to a journal. If the journal is not related to the topic of your research, the article would be rejected even without being subjected to peer review process. Now, let us understand which factors need to be considered for journal selection.

  • Topic of research: Each journal has aims and scopes, which should be explored and matched with the topic of research. Suppose a researcher has written an article on novel therapies for lung cancer, then the researcher should submit the paper to a journal whose name and scope is aligned with lung cancer therapy.
  • Types of articles: Many journals publish a certain type of article. Full length paper will not be published in a journal that publishes only case study. Moreover, a systematic review would not be appropriate for publication in a journal of manuscripts.
  • Journal’s impact factor: Before submitting a paper to a journal, always consider the impact factor of the journal. Greater the impact factor of the journal, higher is the visibility of the article. Papers published in high impact journals usually receive greater citations and credibility.
  • Journal’s target audience: The content of the article should be compliant with the target audience of the journal. If an article is about latest medications and therapies, then the article would be read by a clinical journal and not by a chemical journal. There are many interdisciplinary fields of study, such as robotic surgery in bioinformatics. These papers are read by both surgeons and biomedical engineers.
  • Length of the article: Most journals have laid down strict wordcount restrictions. In general, most biomedical journals do not want abstracts that are more than 250 words. Similarly, most academic journals accept papers that have a wordcount of 3000-5000 words. A pre-press service author education company should be hired to concise the article and abstract and adhere to wordcount restrictions. These wordcount limits are usually displayed in the “Instructions to Authors” Tab of the journal’s website.
  • The type of journal: Science Citation Index (SCI), Open Access (OA), and Hybrid are the three types of journals in academic publishing. The leading publishers are Elsevier, Springer, Nature, Wiley, etc. In general, most Asian researchers publish in SCI journals, while most European researchers prefer to publish in OA journals. Today, hybrid mode of publishing includes the benefits of both SCI and OA journals, so it is now used by researchers all across the world.

Based on these factors, researchers should select three closely related journals for publication of their manuscript.

 

 

 

 

 

Posted on

Academic translation services by Harrisco: top academic company in Seoul, Korea

English is a second language or foreign language in many advanced countries, such as China, Japan, Korea, and Europe. The researchers of these countries have limited working knowledge of English language. They perform their research work in their native language.

This implies that most Chinese, Japanese, Korean, French, Italian, German, and Portuguese researchers need the services of a professional adept at academic translation.

The base language is their native language, while the source language is English. These ESL researchers still need to publish their work in international peer-reviewed English journals. That’s where Harrisco company’s translation services come into effect.

Harrisco is an academic editing and translation company that has been in service in Seoul, Korea since 1997. The professional translators are themselves academics with MS and PhD degrees. They also have additional professional English degrees, such as CELTA, BELS, and TOEFL.

Why choose Harrisco’s translators over other freelance talent? Well, Harrisco is a reputed company that employs only technically qualified translators with five years of experience. Be assured that your academic manuscript is in safe hands with Harrisco. The company has a global network of more than 150 translators, with advanced degrees in science and technology.

These bilingual individuals are an invaluable resource to the field of academic publishing. This is because although English is the lingua franca of scientific publishing, the onus of scientific research has now shifted to ESL countries like China and Korea.

Some ESL researchers may seek the help of their bilingual friends for translation. However, they must be warned that bilingual friends have just elementary fluency in source and target languages. Will they understand technical jargon of science, technology, and medicine in English?

By hiring Harrisco’s academic translators, all technical terminology can be translated correctly from the source to the target language. This ensures that the manuscript is translated with utmost care, ensuring accuracy of content. Thus, authors who are not fluent in English can seek help from Harrisco academic translations and smoothen the publication process of an international journal.

Harrisco’s academic translations have become a name to reckon with in Korea, Japan, and China. The company has a track record of 100% publication output in international peer-reviewed English journals. Even novice researchers may find it difficult to write their manuscript in impeccable English, especially if they live in ESL and EFL countries.

In such cases, it is always preferable to translate the manuscript from the source language to the target language, that is, English. Harrisco offers complete publication support to ESL and EFL authors, ensuring that their work does not face any English language issues. Harrisco is a top brand associated with the world of academic publishing.

 

Posted on

Harrisco offers peer review services to academics

 

Harrisco, a leading academic editing company in Seoul, now offers peer review services to academics. Peer review is the process of evaluating the scientific content of the document. This is a pre-press service that is offered before submitting the manuscript to an international journal.

The content is reviewed by independent researchers through a double-blind peer review process. The content is evaluated for quality, originality, and significance. Based on the reviews, the editors would make an informed decision on whether to publish the article or not in the journal.

Now, let’s understand why peer review process is essential at a pre-press level. Just like English language errors, a translated manuscript also has errors related to content. The researchers from native English speaking countries have a successful track record of international journal publications. They are subject matter experts in their particular field of study.

These subject matter experts will review whether the content meets the rigorous standards of an international SCI (Science Citation Index) journal. Do you know why Harrisco offers double-blind peer review of manuscripts? The names of the authors are not known to the reviewers. At the same time, the names of the reviewers are not known to the authors. As the identities of both the parties are concealed, there is no question of bias based on nationality and gender.

The significance of the peer review process cannot be mitigated or ignored. It is used to validate the authenticity of the content. Peer reviewers are volunteers who get an honorarium to review the manuscript. They are experts both in terms of subject matter and international publications. As they have attended numerous academic conferences, they understand the crux of scientific publishing.

Harrisco services of peer review have now been integrated under the product Quorum. We have a different website for peer review submission. Please peruse through the website www.iquorum.net to understand more about pricing and process. For the double blind review, authors can select upto three reviewers in their field of study. The peer review process makes the content more robust and easy to read.

The errors pointed out may not just be restricted to experiments, they may also be presented in statistical analyses of results. Peer review is thus a very useful process in the development of a manuscript meant for submission to an SCI journal. Come, join hands in improving the quality of the manuscript. Harrisco only employs PhD level peer reviewers for the manuscript.

 

Posted on

Academic Editing services offered by Harrisco: top editing company of academic research papers.

 

Academic editing of research papers is a highly specialized service offered by Harrisco Research Institute. Our company is based in Seoul, South Korea and has been in service since 1997. The documents that usually need editing are thesis, admission essays, research papers, journal manuscripts, books, etc.

Harrisco’s clients are leading universities of Korea, which includes medical colleges and hospitals affiliated to them. Editing is a highly specialized skill, which is performed by highly qualified native English editors from the US, UK, Canada, Australia, New Zealand. They have advanced degrees (MSc/PhD) in their technical field of specialization.

An academic editor would check for errors in grammar, punctuation, logical flow of ideas, organization, and style. Academic editing also involves formatting of research papers according to a specific journal’s style.

In general, medical papers are formatted according to the AMA Manual of Style. Business and engineering papers are formatted according to the Chicago Manual of Style.

Other prominent style guides are the APA, MLA, Harvard, Oxford, and Turabian style of formatting. The reference list and the citation style are always formatted according to a particular style guide. The papers are edited and submitted to leading SCI journals, which follow the system of international peer-review.

Academic editing is essential for ESL (English as Second Language) authors as they have English language issues. The intended meaning of the hypothesis and experiments are conveyed correctly by academic editors.

In Korea, the papers are first translated from Korean to English and then polished by technically qualified editors. As the editors have advanced degrees in science and technology, they have requisite subject matter expertise.

Academic editors themselves have an impressive list of publications. They have participated in academic conferences and understand the nuances of academic editing. The polished manuscript will have four important components: Abstract, Introduction, Methods, Results and Discussion.

Most journals specify that the word count of Abstract needs to be between 250 to 300 words. Thus, academic editors also do word count reduction as per instructions to authors guideline of journals. The international peer-reviewed SCI journals are from leading scientific publishers, such as Elsevier, Springer, Nature, and Wiley.

Journal editors are very strict, so the acceptance of articles depends on the quality of content. Therefore, researchers cannot afford to make mistakes in their content, especially English language errors. Harrisco has an impressive track record of 100% publication output.

 

 

 

 

Posted on

Merck and Ridgeback’s oral antiviral medication, molnupiravir is the first COVID-19 medicine to receive global authorization

 

Molnupiravir is the world’s first antiviral medication in the oral form. This medication has been approved for treating COVID-19 patients who have developed mild to moderate symptoms. This medication is safe for use only in adults who have been tested positive for COVID-19 and who have atleast one underlying disorder that poses as a risk factor. Molnupiravir has been jointly developed by Merck and Ridgeback Biotherapeutics. In the United Kingdom, the medication has been approved for use by the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA). Merck has now requested United States Food and Drug Administration (FDA) to authorize the use of molnupiravir in the US.

Merck would also be filing regulatory applications in the European Union. Following the authorization, Merck received another feather in its cap. The company has always been a pioneer in developing breakthrough medications that control the global pandemic. The life-saving medication will not only save the life of COVID-19 patients, but also be an effective oral therapeutic for lung disorders. This is a major boost to COVID-19 treatment, which included only vaccines as a preventive measure.

The phase 3 clinical trial of molnupiravir was known as MOVe-OUT clinical trial. The positive results of this clinical trial compelled the authorities to give a positive feedback. In this trial, 800 mg of molnupiravir was administered orally to COVID-19 patients who are neither hospitalized nor vaccinated. The medication was given twice daily after laboratory tests confirmed that their symptoms were mild to moderate. These patients had at least one risk factor, such as diabetes and heart disease.

The collaboration between patients and physicians seemed to be successful in this clinical trial. This is an extraordinary effort in controlling the global pandemic. The efforts of all brave volunteers of this clinical trial must be applauded. Merck is now working hard to gain licenses from other global regulatory authorities in order to broaden the access to this wonder drug globally. Let’s understand what is molupiravir in biological terms. Well, it is a potent form of a ribonucleoside, preventing SARS-CoV-2 from replicating and proliferating. This virus is the leading cause of COVID-19.

The efficacy of molnupiravir is now being evaluated in the prophylaxis MOVe-AHEAD study. This phase 3 study would be performed in a randomized, double-blind manner; however, the control would be a placebo and the clinical trial would be in a multicentre setting. The goal is to evaluate whether molnupiravir is effective in controlling and preventing COVID-19 in household patients. The clinical trial patients were not vaccinated for SARS-CoV-2. Moreover, they had at least one underlying disease that could complicate their case of COVID-19.

 

 

Posted on

Atherosclerotic Cardiovascular Disease (ASCVD), world’s #1 killer after cancer, will now be controlled by Novartis and Global Heart Hub

 

The Invisible Nation program has been launched recently by Novartis and Global Heart Hub. Under this program, a network of organizations will dedicate to improve the health of patients with cardiovascular diseases (CVD), helping them to manage the systemic changes that occur in atherosclerotic cardiovascular disease (ASCVD).

Did you know that about 15 million die due to ASCVD each year? Well, the program will not prevent such deaths but also help in reducing the economic burden of $1 trillion that is accrued as the annual cost of CVD. Although it is possible to prevent the death of most patients with ASCVD, most countries have failed to meet the WHO guidelines for reducing the mortality of CVD by 25% until 2025.

The Invisible Nation program will estimate the costs of managing ASCVD to patients and the society as a whole. It will coerce government NGOs to have a high-level of commitment in tackling the disease. Thus, it would create an environment for building new partnerships and new models to access healthcare services. These efforts would reduce the mortality of ASCVD significantly on a worldwide scale.

According to the Global Heart Hub’s executive director, the number of deaths caused by ASCVD is approximately 60% lesser than the number of deaths caused by cancer. Millions of people die from ASCVD each year and it is a terrible shock to everyone related to patients.

This shocking news can be prevented completely in about 80% of the cases. Patient organizations should provide support by providing education and guidance for better prognosis. This would reduce the high number of premature deaths. A change can be brought about in the overall management of the disease by increasing awareness among patients.

The Invisible Nation program will promote policies that transform the way governments controls the existing healthcare systems. Thus, many patient organizations can work together to decrease the growing trajectory of ASCVD deaths. Global Heart Hub will be working with major patient organizations to come up with a final action plan.

They will highlight innovative strategies to governments and healthcare systems in order to reduce the mortality rate of CV by 25%, according to the WHO guideline. The goal has to be achieved by the end of the year 2025. Novartis will be assisting in community programs by helping in networking of members seeking information and evidence of ASCVD. Thus, it will bring about a cooperation between local healthcare system, government authorities, and policymakers.

 

 

Posted on

African countries will receive 17 million doses of COVID-19 vaccine manufactured by Johnson & Johnson

 

To control the global pandemic of COVID-19, US government has decided to donate 17 million doses of single-shot COVID-19 vaccine to African countries. The vaccine has been manufactured by the reputed company Johnson & Johnson.

Under the COVAX program, the US government would be providing to African countries these doses of COVID-19 vaccine. Gavi, the Vaccine Alliance of the WHO would be supervising this massive initiative of the US government. Furthermore, the US government has committed to donate about 50 million doses of the vaccine produced by Johnson & Johnson company.

Through the COVAX program of the WHO, the vaccines would be disbursed to people living in 40 countries spread across four continents. Currently, approximately 25 million doses of the vaccine have already been shipped internationally.

The corporate leadership of Johnson & Johnson has endorsed this initiative, reflecting on the need for life-saving doses of COVID-19 in poorer countries that need the most of medications in the pandemic. The US government has shown strong leadership skills in promising to donate so many million doses of the single-shot vaccine.

The company leaders have promised to accelerate the disbursement of vaccine on a global scale. The end of the pandemic may soon be possible with these positive strategies. The African Vaccine Acquisition Trust (AVAT) would be assisting the donation drive of the US government.

The trust is working independently in procuring more vaccines of COVID-19 for the African Union of countries. The US government’s largesse is evident from the fact that even Johnson & Johnson has promised to 900 million doses of single-shot vaccines by 2022, under the COVAX program.

According to chief scientific officer of Johnson & Johnson company, nobody is immune from contracting COVID-19 until everyone has been vaccinated. Even a single shot vaccine has to be compatible with the standard channels of distribution.

This vaccine is crucial in controlling the COVID-19 pandemic, so the whole world needs a strong vaccination drive to put an end to the pandemic. The US government has selected needy countries for the vaccine donation drive.

Global NGOs like the UNICEF would be assisting WHO in disbursing vaccines through the COVAX program. Logistics and supply chain would be handled by Johnson & Johnson company. The world leaders have promised to reach the vaccine safely to needy countries of this world.

 

 

Posted on

Researchers at Laussane University hospital discover a highly effective antibody against SARS-CoV-2

 

A newly discovered antibody was isolated from the lymphocytes of patients with COVID-19. These patients were enrolled in a research study conducted by Laussane University Hospital. This antibody has been found to be very powerful in fighting against SARS-CoV-2. After performing structural analysis of the antibody, the researchers found that it does not associate itself with mutations of the spiked protein.

The cells expressing the ACE2 receptor are prevented from binding to the spike protein by the newly discovered antibody. The COVID-19 virus uses the spike protein to enter the body and infect the cells of the lungs. This implies that the antibody fights against the replication of the virus, helping immune cells in eliminating SARS-CoV-2 from the human body.

In vivo tests confirmed the antiviral properties of the antibody, which was administered into some specimens that had contracted a high infection of the virus. This antibody offers a lasting effect of protection against coronavirus infection. In general, a conventional antibody can provide protection against infection for about 3-4 weeks.

But this antibody offers protection for about 4-6 months, making it an attractive treatment that prevents infection in unvaccinated people or in vaccinated people with compromised immunity. These patients, cancer patients, or those who have undergone organ transplantation in these times should receive at least two to three doses of antibody injections in a year. The clinical trial of the drug containing this new antibody would begin in the latter half of the year 2022.

In Europe, a lot of efforts have been made in drug discovery, especially in times of COVID-19 pandemic. This newly discovered antibody can be very effective in fighting COVID-19 infection. This new form of treatment should be made available in the form of a drug, enhancing protection of patients with weak immune systems. However, it may be noted that the antibody cannot be replacement to COVID-19 vaccines, which are still most effective in controlling the pandemic.

 

 

Posted on

Most variants of coronavirus can be handled effectively by vaccines

 

According to researchers at the University of Yale, Moderna and Pfizer-BioNTech vaccines are the most commonly used vaccines against coronavirus. These vaccines are quite effective in combating multiple variants of SARS-CoV-2, that is, the virus that causes COVID-19. These findings were recently published in the noted medical journal Nature. Moreover, it was found that following vaccination, people infected with coronavirus showed an immune response that was more robust to all variants of coronavirus. The recent Delta variant of the virus has been reported in vaccinated people, raising doubts about the efficacy of the vaccine.

The research study found that vaccines helped the immune system fight back effectively against even new variants of the infection by inducing the production of a large number of antibodies against new variants, including the Delta. Moreover, the authors of the study urged individuals to take two doses of the vaccine. Furthermore, individuals were also requested to take booster shots to combat variants, such as Delta of the virus. The study was conducted on 40 healthcare workers from November 2020 to January 2021. This study included subjects who had not been vaccinated at the start of the study. During the course of the study, several groups of participants received two doses of the Moderna or Pfizer-BioNTech mRNA vaccines.

The blood samples of the participants were exposed to 16 different variants of SARS-COV-2 by researchers. The variants included the most powerful Delta variant, which is extensively circulating in the United States. Then, they measured the response of antibodies and T cells to all the variants. It must be noted that none of the participants were infected with the virus. In all the blood samples, the response of the immune cells was enhanced. Nevertheless, the intensity of the immune cell response depended on the variant and the participant. A robust response was noted in individuals exposed to Delta variant.

Breakthrough cases were those that showed an infection develop despite being vaccinated. These cases were caused by Delta variant but it does not mean that the vaccines failed in providing protection against coronavirus. Instead, it means that Delta variant was so infectious that it overcame the immune defense system of patient’s body. However, patients who had been vaccinated before contracting the infection showed a lesser severity in the infection. Compared to other variants, Delta is the most infectious one because it is highly transmissible. The participants were divided into groups: those who had been vaccinated before being infected with COVID-19 and those who had not been vaccinated.

The participants who had been infected before being vaccinated showed an immune response that was more robust than the participants who were not infected with the virus. The researchers were of the view that the robust immune response was like a first dose of the vaccine, recovering participants from their initial infection. The vaccinated participants should have received a booster shot, which would have increased the number of antibodies and T cells that offer protection against infections.